3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
3
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Colonic Neoplasms
3
Adenoma
2
Venous Thromboembolism
1
Urinary Bladder Neoplasms
1
Thrombocytopenia
1
Soft Tissue Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Node Positive HER2 Negative Breast Cancer
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Myocardial Infarction
1
Multiple Myeloma
1
Hereditary Sensory and Autonomic Neuropathies
1
Hematuria
1
Hematologic Diseases
1
Glioblastoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Adenomatous Polyps
1
Adenocarcinoma of Lung
1
Acute Coronary Syndrome
1
Interventions
Melphalan
16
Cyclophosphamide
14
Dexamethasone
13
fludarabine phosphate
12
Filgrastim
11
Antilymphocyte Serum
11
fludarabine
8
Radiotherapy
8
Mycophenolic Acid
8
Cyclosporine
8
Busulfan
8
Whole-Body Irradiation
7
Tacrolimus
7
Peripheral Blood Stem Cell Transplantation
7
Methylprednisolone
6
Lenalidomide
6
Bortezomib
6
pomalidomide
5
Rituximab
5
Methotrexate
5
Granulocyte Colony-Stimulating Factor
5
Cord Blood Stem Cell Transplantation
5
Calcium Dobesilate
5
Flow Cytometry
4
Etoposide
4
Arsenic Trioxide
4
liposomal doxorubicin
3
Thalidomide
3
Surveys and Questionnaires
3
Stem Cell Transplantation
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasms, Plasma Cell
×
Aspirin
×
Clear all
NCT00790842
2018-10-24
PrE1003
PrECOG, LLC.
Phase 1/2
Terminated
63 enrolled
14 charts